AVENTIS PHARMA S.A.
Patent Owner
Stats
- 413 US PATENTS IN FORCE
- 2 US APPLICATIONS PENDING
- Feb 15, 2018 most recent publication
Details
- 413 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 10,904 Total Citation Count
- Dec 13, 1978 Earliest Filing
- 641 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0042,941 CABAZITAXEL AND ITS USE FOR TREATING METASTATIC PROSTATE CANCERSDec 14, 16Feb 15, 18[A61K]
2017/0183,736 MUTATIONS OF THE PARKIN GENE, COMPOSITIONS, METHODS AND USESNov 04, 16Jun 29, 17[C12Q, C12N]
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
9540693 Mutations of the parkin gene, compositions, methods and usesAug 07, 14Jan 10, 17[C12Q, C12N, C07K]
9309210 Crystalline form of cabazitaxel and process for preparing the sameJun 11, 14Apr 12, 16[C07D]
9126969 Pyrazolylbenzimidazole derivatives, compositions containing them and use thereofDec 18, 08Sep 08, 15[C07D]
8852878 Method for identifying an antagonist of guanine nucleotide releasing factor 1Aug 03, 11Oct 07, 14[G01N]
8846959 Crystalline forms of dimethoxy docetaxel and methods for preparing the sameFeb 15, 13Sep 30, 14[C07D]
8709426 Nucleotide sequence coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic usesOct 05, 07Apr 29, 14[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2015/0374,717 CABAZITAXEL AND ITS USE FOR TREATING METASTATIC PROSTATE CANCERSAbandonedSep 03, 15Dec 31, 15[A61K]
2014/0350,272 CRYSTALLINE FORMS OF DIMETHOXY DOCETAXEL AND METHODS FOR PREPARING THE SAMEAbandonedAug 06, 14Nov 27, 14[C07D]
2014/0127,202 ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECANAbandonedJan 13, 14May 08, 14[A61K]
2014/0056,996 ANTITUMORAL COMBINATION COMPRISING CABAZITAXEL AND CISPLATINAbandonedAug 22, 13Feb 27, 14[A61K]
2014/0030,265 MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS METHODAbandonedJun 28, 13Jan 30, 14[A61K, C07K]
2013/0210,898 RECOMBINANT VIRUSES AND THEIR USE FOR TREATMENT OF ATHEROSCLEROSIS AND OTHER FORMS OF CORONARY ARTERY DISEASE AND METHOD, REAGENT, AND KIT FOR EVALUATING SUSCEPTIBILITY TO SAMEAbandonedFeb 08, 13Aug 15, 13[A61K]
2013/0184,205 ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOFAbandonedMar 04, 13Jul 18, 13[A61K]
8431119 Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseasesExpiredAug 22, 07Apr 30, 13[A61K, A01N, C12N]
2013/0101,524 SEMULOPARIN FOR THE EXTENDED PREVENTION OF A MORTALITY AND/OR MORBIDITY EVENT IN A PATIENT HAVING UNDERGONE HIP FRACTURE SURGERYAbandonedDec 12, 12Apr 25, 13[A61K]
2013/0102,565 SEMULOPARIN FOR THE PREVENTION OF A MORTALITY AND/OR MORBIDITY EVENT IN A PATIENT UNDERGOING MAJOR ORTHOPEDIC SURGERYAbandonedDec 12, 12Apr 25, 13[A61K]
2013/0102,566 SEMULOPARIN FOR USE AS AN ANTITHROMBOTIC TREATMENT IN HIP REPLACEMENT SURGERY WITH IMPROVED SAFETY IN TERMS OF CLINICALLY RELEVANT BLEEDINGS AND MAJOR BLEEDINGSAbandonedDec 12, 12Apr 25, 13[A61K]
2012/0322,759 SEMULOPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS RECEIVING CHEMOTHERAPYAbandonedMay 11, 12Dec 20, 12[A61K, G06Q, A61P]
2012/0277,235 Compositions For Topical Application Having Androgenic ActionsAbandonedMar 30, 12Nov 01, 12[A61K, A61P]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.